You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Associations between adverse eventsa, regimen, age, and immunosuppression, n = 726

From: Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study

Covariates   Univariable Multivariable
n c OR p a OR SE p 95% CI
Regimen (Wald test for overall variable in adjustment model, p = 0.065)
 3RHb 399 1 (ref)   1 (ref)    
 3RPHc 306 0.57 0.097 0.60 0.209 0.141 0.30–1.18
 Otherd 21 3.99 0.012 2.37 1.360 0.131 0.78–7.30
Age
< 35 yrs 561 1 (ref)   1 (ref)    
 > 35 yrs 165 3.62 < 0.001 2.51 2.25 0.024 1.13–5.60
Immunosuppression
 No immunosuppression 603 1 (ref)   1 (ref)    
 Immunosuppression, any 123 3.39 < 0.001 1.55 0.66 0.306 0.67–3.57
  1. OR Odds ratio, SE standard error
  2. aAdverse effects leading to termination or interruption of treatment, n = 47
  3. b3HR, 3 months daily rifampicin and isoniazid
  4. c3RPH, 12 weekly doses of rifapentine and isoniazid
  5. dOther; rifampicin monotherapy (n = 5), isoniazid monotherapy (n = 13), combination therapy for TB disease (n = 2) and 1 missing information